Theralase Technologies Inc. V.TLT

Theralase® Research - One of the Top 10 Most Downloaded Pape

[made2last]

Hi All;

 

Very positive statement by our Interim CEO

 

Dr. Arkady Mandel M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer of Theralase® stated, “This is another milestone of excellence achieved by Theralase®. These pre-clinical results led a logical progression to our successfully completed Phase Ib NMIBC clinical study, which demonstrated the safety, pharmacokinetics and efficacy in a first in-human clinical study.

 

The success in the Phase Ib NMIBC clinical study has led to the impressive preliminary results demonstrated in the Phase II NMIBC clinical study, focused primarily on efficacy and secondarily on safety. In the future, I foresee great potential for Theralase® Anti-Cancer Therapy (“ ACT ”) to deliver a safe and effective anti-cancer treatment for numerous cancer indications with high unmet needs."

Thanks;

made2last

[wildbird1]

made2last. You beat me to it. Definitively very positive. Sooner or later something very positive is going to happen with TLT.

[made2last]

Hi wildbird1; Happy for an unexpected NR positive beginning on a Friday. Normally they offer a NR on a Monday or Tuesday. The best to you; made2last  

[fredgoodwinson]

People don`t have to buy the stock on the strength of these positive announcements - it`s up to them really.

[jicoop]

another important statement we don't see mentioned too often , but VERY important IMHO . Coop In conclusion, the Publication stated that, “Combination of TLD-1433 instillation and the use of green PDT activation light results in a steep PDT gradient providing one avenue to protect normal muscle function. The high selective uptake of TLD-1433 is very favorable to compensate for